

JOHNSON & JOHNSON
PATENT LAW DEPARTMENT
OFFICE OF GENERAL COUNSEL

Johnson & Johnson Pharmaceutical Research & Development, LLC
3210 Merryfield Row, San Diego, California 92121

RECEIVED

MAR 01 2004

OFFICE OF PETITIONS

FACSIMILE TRANSMISSION COVERSHEET

DATE: 25 March 2002

TO: Examiner W. MOORE
Art Unit: 1652

COMPANY: United States Patent & Trademarks Office

FACSIMILE NO.: (703) 872 - 9306

FROM: John W. Wallen, III, Esq.
Johnson & Johnson

TELEPHONE NO.: (858) 784 - 3239
FACSIMILE NO.: (858) 784 - 3044

NUMBER OF PAGES INCLUDING THIS COVER SHEET: 4


- NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Serial No.: 10/015,989
Filed: 10 December 2001
Inventor: DARROW et al.

(IF THERE IS A PROBLEM WITH THIS TRANSMISSION PLEASE CALL (858) 784-3249)

CONFIDENTIALITY NOTICE

This message is intended only for the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message solely to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U.S. postal service. Thank you.



DOCKET NO. ORT-1552

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Andrew L. DARROW, Jenson QI, and Patricia ANDRADE-GORDON

Serial No.: 10/015,989 Art Unit: 1652

Filed: 10 December 2001 Examiner: MOORE, W.

For: ZYMOGEN ACTIVATION SYSTEM

RECEIVED

MAR 01 2004

OFFICE OF PETITIONS


I hereby certify that this correspondence is being facsimile
transmitted to the Patent and Trademark Office Fax No.
(703) 872 - 9306 on:

25 March 2002

(Date of Deposit)

John W. Wallen, III

(Name of applicant, assignee, or Registered Representative)



(Signature)

25 March 2002

(Date of Signature)

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES


Sir:

In response to the Notice to Comply, mailed 6 March, 2002 Applicants hereby invoke 37 C.F.R. 1.821(e). The computer readable form in this application, 10/015,989 is identical with that filed in Application Number 09/386,642, filed 31 August 1999, then in accordance with 37 C.F.R. 1.821(e), please use the last-filed computer readable form filed in that application as the computer readable

ORT-1552
Requirements For Patent Applications Containing Nucleotide
Sequence And/Or Amino Acid Sequence Disclosures

form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing for Application Serial No. 09/386,642 was included with the submission of the original application on 31 August 1999. A copy of the Notice to Comply is attached hereto.

Respectfully submitted,



John W. Wallen, III

Reg. No. 35,403

Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(858) 784-3239
DATE: 25 March 2002




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/015,989	12/10/2001	Andrew Darrow	ORT-1552

Philip S. Johnson, Esq.
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003



CONFIRMATION NO. 3866

FORMALITIES LETTER



OC000000007589559

RECEIVED

MAR 01 2004

Date Mailed: 03/06/2002

OFFICE OF PETITIONS

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE